Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock
Status:
Completed
Trial end date:
2019-09-27
Target enrollment:
Participant gender:
Summary
This is a prospective, multi-centric, randomized, double-blind, parallel, controlled
phase-III efficacy clinical study of PMZ-2010 therapy in patients with hypovolemic shock.
Centhaquine (previously used names, centhaquin and PMZ-2010; International Non-proprietary
Name (INN) recently approved by WHO is centhaquine) has been found to be an effective
resuscitative agent in rat, rabbit and swine models of hemorrhagic shock, it decreased blood
lactate, increased mean arterial pressure, cardiac output, and decreased mortality. An
increase in cardiac output during resuscitation is mainly attributed to an increase in stroke
volume. Centhaquine acts on the venous α2B-adrenergic receptors and enhances venous return to
the heart, in addition, it produces arterial dilatation by acting on central α2A-adrenergic
receptors to reduce sympathetic activity and systemic vascular resistance.